Tomorrow.Bio secures initial seed funding to bring human cryopreservation services to New York, California and Florida.
European cryonics lab Tomorrow.Bio today secured the first close of a €5 million seed funding round to support its international expansion and R&D efforts. The Berlin-based startup says it plans to extend its operations into the United States, beginning with initial bases in New York, California and Florida, while also increasing its investment in research to improve the quality of human cryopreservation.
Founded in 2020 by former cancer researcher Dr Emil Kendziorra and Fernando Azevedo Pinheiro, Tomorrow.Bio offers cryogenic preservation services to individuals who wish to be stored at ultra-low temperatures with the hope of being revived in the future.
As Kendziorra said in a recent article in Longevity.Technlogy: “The primary goal of human biostasis is to preserve the potential for life by pausing it until future medical advancements can address the cause of death, aging, and restore the individual to full health.”
The catch, of course, is that there is currently no way to bring a cryopreserved body back to life, but Kendziorra believes that biostasis is the “only alternative” to death at this point in time. “At the very minimum, cryopreservation gives you a chance,” he told us back in 2022.
Some people clearly agree. Tomorrow.Bio says it has already cryopreserved 20 people and 10 pets, and over 800 individuals have signed long-term contracts, which the company claims represents a “total contract value” exceeding €160 million.
The cryopreservation process begins immediately after legal death is declared. Tomorrow.Bio deploys specialized “cryo-ambulances” operated by standby teams who administer oxygen, perform chest compressions and begin the cooling process while transporting the body. Once at the facility, bodily fluids are replaced with a cryoprotectant solution to prevent ice crystal formation during deep freezing, aiming to halt biological decay in the shortest possible time.
In Europe, Tomorrow.Bio’s teams are stationed in Berlin and Zurich, with new locations being developed to enable faster on-site response times. It is expected that the US expansion will adopt a similar localized cryonics service model.
The company currently operates in partnership with the non-profit European Biostasis Foundation, based in Switzerland, which provides the storage facilities where cryopreserved patients are kept in vacuum-insulated steel “dewars” filled with liquid nitrogen. These containers require no electricity and are designed to maintain conditions at minus 196 degrees Celsius indefinitely.
The funding round was co-led by French venture capital firm Blast.Club and Truventuro, and included participation from angel investors, high-net-worth individuals and existing backers.
“Companies like Tomorrow Bio are on the absolute forefront of visionary longevity approaches,” said Truventuro founder Nils Regge, a speaker at next month’s Founders Longevity Forum in London. “We’re very happy to support these types of moonshots, that might not just have a big impact on the extension of life span but are also huge business opportunities.”
“Tomorrow Bio’s cutting-edge technology is revolutionizing the way we view life and death,” said Blast.Club CEO Anthony Bourbon.
